NCT06449781View on ClinicalTrials.gov

177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 9, 2025

Primary Completion Date

November 30, 2030

Study Completion Date

November 30, 2030

Conditions
Prostate Cancer
Interventions
DRUG

Lutetium (177Lu) vipivotide tetraxetan

The intervention will consist of a single administration of 7,4 GBq of lutetium (177Lu) vipivotide tetraxetan

Trial Locations (1)

44-101

RECRUITING

Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice

All Listed Sponsors
lead

Maria Sklodowska-Curie National Research Institute of Oncology

OTHER